Cargando…

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

BACKGROUND: Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive response rates and durable disease remission...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, T A, Yarchoan, M, Jaffee, E, Swanton, C, Quezada, S A, Stenzinger, A, Peters, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336005/
https://www.ncbi.nlm.nih.gov/pubmed/30395155
http://dx.doi.org/10.1093/annonc/mdy495